HEMOPROTECTIVE AGENT
FIELD: medicine; pharmaceutics.SUBSTANCE: invention refers to medicine and pharmaceutics and can be used for stimulating hematopoiesis processes in chemotherapy of tumor diseases. That is ensured by using NF-κB inhibitors as a hemoprotective agent in cytostatic effects.EFFECT: invention provides effective hemoprotective action in cytostatic effects by stimulating functions of hematopoietic progenitor cells in the post-cytostatic period.1 cl, 3 tbl, 1 ex.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 30. Juni Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZYUZKOV GLEB NIKOLAEVICH [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-06-30, Last update posted on www.tib.eu: 2022-05-31, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
RU2725135 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA004248228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA004248228 | ||
| 003 | DE-627 | ||
| 005 | 20230504062044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210529s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA004248228 | ||
| 035 | |a (EPA)RU2725135 | ||
| 035 | |a (EPA)71510216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZYUZKOV GLEB NIKOLAEVICH |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HEMOPROTECTIVE AGENT |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-06-30, Last update posted on www.tib.eu: 2022-05-31, Last updated: 2023-02-09 | ||
| 520 | |a FIELD: medicine; pharmaceutics.SUBSTANCE: invention refers to medicine and pharmaceutics and can be used for stimulating hematopoiesis processes in chemotherapy of tumor diseases. That is ensured by using NF-κB inhibitors as a hemoprotective agent in cytostatic effects.EFFECT: invention provides effective hemoprotective action in cytostatic effects by stimulating functions of hematopoietic progenitor cells in the post-cytostatic period.1 cl, 3 tbl, 1 ex | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MIROSHNICHENKO LARISA ARKADEVNA |4 aut | |
| 700 | 0 | |a POLYAKOVA TATYANA YUREVNA |4 aut | |
| 700 | 0 | |a SIMANINA ELENA VLADISLAVOVNA |4 aut | |
| 700 | 0 | |a STAVROVA LARISA ALEKSANDROVNA |4 aut | |
| 700 | 0 | |a ZHDANOV VADIM VADIMOVICH |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 30. Juni |
| 773 | 1 | 8 | |g year:2020 |g day:30 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71510216/publication/RU2725135A1?q=RU2725135 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 30 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 30 |c 06 | ||